Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

731 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Sharman JP, et al. Among authors: karlsson k. Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2. Lancet. 2020. PMID: 32305093 Free PMC article. Clinical Trial.
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC. Sharman JP, et al. Among authors: karlsson k. Leukemia. 2022 Apr;36(4):1171-1175. doi: 10.1038/s41375-021-01485-x. Epub 2022 Jan 1. Leukemia. 2022. PMID: 34974526 Free PMC article. No abstract available.
Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
Mulligan SP, Karlsson K, Strömberg M, Jønsson V, Gill D, Hammerström J, Hertzberg M, McLennan R, Uggla B, Norman J, Wallvik J, Sundström G, Johansson H, Brandberg Y, Liliemark J, Juliusson G; Scandinavian and Australasian Leukaemia Lymphoma Groups (Allg). Mulligan SP, et al. Among authors: karlsson k. Leuk Lymphoma. 2014 Dec;55(12):2769-77. doi: 10.3109/10428194.2014.893306. Epub 2014 Apr 16. Leuk Lymphoma. 2014. PMID: 24524339 Clinical Trial.
Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients.
Karlsson K, Strömberg M, Liliemark J, Delannoy A, Johnson SA, Porwit A, Kimby E, Lärfars G, Cristiansen I, Nilsson G, Celsing F, Sundström G, Luthman M, Tidefelt U, Wallvik J, Juliusson G. Karlsson K, et al. Br J Haematol. 2002 Mar;116(3):538-48. doi: 10.1046/j.0007-1048.2001.03296.x. Br J Haematol. 2002. PMID: 11849209 Free article. Clinical Trial.
Satisfactory outcome after intensive chemotherapy with pragmatic use of minimal residual disease (MRD) monitoring in older patients with Philadelphia-negative B cell precursor acute lymphoblastic leukaemia: a Swedish registry-based study.
Bergfelt E, Kozlowski P, Ahlberg L, Hulegårdh E, Hägglund H, Karlsson K, Markuszewska-Kuczymska A, Tomaszewska-Toporska B, Smedmyr B, Åström M, Amini RM, Hallböök H. Bergfelt E, et al. Among authors: karlsson k. Med Oncol. 2015 Apr;32(4):135. doi: 10.1007/s12032-015-0582-2. Epub 2015 Mar 22. Med Oncol. 2015. PMID: 25796502
Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis.
Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, Scielzo C, Laoutaris N, Karlsson K, Baran-Marzsak F, Tsaftaris A, Moreno C, Anagnostopoulos A, Caligaris-Cappio F, Vaur D, Ouzounis C, Belessi C, Ghia P, Davi F, Rosenquist R, Stamatopoulos K. Murray F, et al. Among authors: karlsson k. Blood. 2008 Feb 1;111(3):1524-33. doi: 10.1182/blood-2007-07-099564. Epub 2007 Oct 24. Blood. 2008. PMID: 17959859 Free article.
High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden.
Kozlowski P, Åström M, Ahlberg L, Bernell P, Hulegårdh E, Hägglund H, Karlsson K, Markuszewska-Kuczymska A, Tomaszewska-Toporska B, Smedmyr B, Amini RM, Hallböök H; Swedish Adult ALL Group. Kozlowski P, et al. Among authors: karlsson k. Eur J Haematol. 2014;92(5):377-81. doi: 10.1111/ejh.12269. Epub 2014 Feb 21. Eur J Haematol. 2014. PMID: 24443846
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.
Sylvan SE, Asklid A, Johansson H, Klintman J, Bjellvi J, Tolvgård S, Kimby E, Norin S, Andersson PO, Karlsson C, Karlsson K, Lauri B, Mattsson M, Sandstedt AB, Strandberg M, Österborg A, Hansson L. Sylvan SE, et al. Among authors: karlsson k, karlsson c. Haematologica. 2019 Apr;104(4):797-804. doi: 10.3324/haematol.2018.200204. Epub 2018 Nov 22. Haematologica. 2019. PMID: 30467205 Free PMC article. Clinical Trial.
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
Winqvist M, Asklid A, Andersson PO, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Hansson L, Österborg A. Winqvist M, et al. Among authors: karlsson k, karlsson c. Haematologica. 2016 Dec;101(12):1573-1580. doi: 10.3324/haematol.2016.144576. Epub 2016 May 19. Haematologica. 2016. PMID: 27198718 Free PMC article.
731 results